Wuhan Landing Medical Raises Tens of Millions in Funding, Plans Nationwide Rollout of Third-Party Pathology Diagnostic Centers

VCBeat (WeChat ID: vcbeat) has learned that Wuhan Landing Medical High-Tech Co., Ltd. (hereinafter referred to as “Wuhan Landing”) recently completed a financing round worth tens of millions of yuan on May 23. Dr. Sun Xiaorong stated that this round was led by Xiantong Capital, with existing shareholders Daotong Investment and Fenyi Capital participating as follow-on investors.

Wuhan Landing, established in 2001, is a technology-driven company integrating industry-academia-research and clinical services in AI-powered cytopathology. The company’s independently developedFully Automated Digital (Remote) Pathology Cytology AnalyzerIt successfully overcame the limitations of microscopy and human diagnostic expertise by employing artificial intelligence to enable machines to learn from millions of provided samples, thereby mastering the identification of cancer cells, precancerous lesions, and normal cells. This allows for the precise differentiation between normal cervical cells and cancer cells, while also possessing the capability for continuous learning.

Traditional manual diagnosis suffers from drawbacks such as strong subjectivity, low sensitivity, low efficiency, and a lack of quality control. With the assistance of artificial intelligence technology, physicians can now achieve precise, quantitative, and objective testing, thereby enabling automation, intelligence, standardization, and network connectivity in diagnostic processes.

Wuhan Landing Medical High-Tech Co., Ltd. completed in 2016Cytopathology Cloud Platformdevelopment and deployment, enabling the upload of raw data scanned by terminals to the cloud for automated detection and diagnosis by the cloud platform. The diagnostic reports are verified through a three-tier quality control system in the backend and ultimately transmitted back to each terminal. The cloud platform canIntegrate High-Quality Cytopathologist Resources Across Regions, data collected in the cloud can continuously optimize machine diagnostic algorithms, thereby steadily improving the accuracy of cloud-based diagnostics.

Currently, Wuhan Landing Medical High-Tech Co., Ltd.'s equipment has obtained clinical certification and approval from China's CFDA, the EU CE mark, and the US FDA (Class I). Its products have been deployed in nearly 300 hospitals across China, with millions of early cytopathological screening tests completed to date. The company is also actively collaborating with overseas medical partners to expand its international market presence.

Sun Xiaorong, who has studied and worked at Memorial Sloan Kettering Cancer Center in New York and the BC Cancer Agency in Canada, is well-versed in the early screening guidelines for cancers such as cervical and lung cancer in developed countries.She stated that with the continuous advancement of healthcare reform policies, tiered diagnosis and treatment systems and third-party pathology diagnostic centers have ushered in rapid industry growth. In the context of imbalanced medical resource allocation in China, automated and intelligent testing along with third-party laboratories are bound to receive significant attention. Over the next three years, the company plans to establish its third-party pathology diagnostic centers in major provincial capital cities across China.

On April 14 this year, at the 2017 United Nations Symposium on Procurement of Health Care Products held in Wuhan, “Landing,” an AI-powered cervical cancer diagnosis robot developed by Wuhan Landing, made a stunning debut and engaged in a “man-machine competition” with five pathology experts.

After the competition,The diagnostic results submitted by the robot were completely consistent with those of the experts., which will effectively address the shortfall in China’s grassroots healthcare system, where a shortage of cytopathology technicians has hindered the ability to meet government cervical cancer screening targets with both quality and quantity assured. For more details, please click “Millions of Databases: Wuhan Landing Medical’s Cervical Cancer Screening Pathology Robot, Landing, Has Received Clinical Certification in Multiple Countries》

Lead InvestorXiantong CapitalIt is a professional investment firm specializing in life sciences and biomedicine, boasting leading expertise and extensive project execution experience in China’s biology, pharmaceutical, and healthcare investment sectors. Xiantong Capital maintains offices in Shenzhen, Beijing, Suzhou, and Chicago (USA), assembling an investment and advisory team composed of industry experts, scientists, and investors from the life sciences field.

The firm has received numerous awards, including being named among the “Top 50 Best Chinese Venture Capital Firms in China (2016)” and the “Top 10 Best Investment Firms in the Biopharmaceutical Sector of China’s Healthcare and Medical Services Industry (2016),” while its Founding Partner, Liu Mulong, was honored with the “Distinguished Investor” title.

InvestorDaotong InvestmentAs a leading venture capital firm in China’s healthcare sector, DaoTong Investment has established an extensive investment portfolio within the industry. Renowned for its professionalism and focused approach, DaoTong Investment currently prioritizes key areas such as healthcare services, medical devices, and biotechnology. Its invested projects span diverse sub-sectors, including primary care chain services (covering pediatrics, public health, sports rehabilitation, etc.), medical robotics, genetic testing, tumor cell screening, medical artificial intelligence, new media in healthcare and online physician communities, and healthcare entrepreneurship services.

Recognized as one of the Top 10 Best Investment Cases in the Medical Services Sector and one of the Top 10 Best Investment Cases in the Medical Devices Sector in China’s Healthcare and Health Services Industry by CVSource in 2016. Named the Most Promising Investment Firm of the Year at the 2016 Precision Medicine Innovation Forum and the 6th China Healthcare Entrepreneurs Conference.